About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ARDX - Ardelyx| Previous Close | $6.74 | Open | $6.67 |
| Volume | 982.9K | Market Cap | 159.63M |
| Yield | Last Dividend |
| Ardelyx Stock Plummets As Review Period ... | 04/30/21 |
| The FDA has extended the Prescription Drug User Fee Act (PDUFA) date for Ardelyx Inc's (NASDAQ: ARDX ) tenapanor for the control of serum phosphorus i... | |
| The Daily Biotech Pulse: Clinical Setbac... | 04/29/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Ax... | |
| The Week Ahead In Biotech (April 25-May ... | 04/24/21 |
| Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ ) an... | |
| 42 Biggest Movers From Yesterday | 04/16/21 |
| Gainers Esports Technologies, Inc. (NASDAQ: EBET ) shares jumped 507% to settle at $36.42 on Thursday. agilon health, inc. (NYSE: AGL ) gained 34.8% t... | |
| Analyzing Ardelyx (NASDAQ:ARDX) and Rige... | 03/14/21 |
| Ardelyx (NASDAQ:ARDX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better stock? We will compare the... | |
| Ardelyx (NASDAQ:ARDX) Posts Quarterly Ea... | 03/11/21 |
| Ardelyx (NASDAQ:ARDX) announced its quarterly earnings data on Sunday. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing the... | |
| Ardelyx Reports Fourth Quarter and Full ... | 03/08/21 |
| FREMONT, Calif. and WALTHAM, Mass., March 8, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing inno... | |
| Ardelyx Is it time to Buy before this we... | 03/04/21 |
| Ardelyx announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| Ardelyx (ARDX) May Report Negative Earni... | 02/26/21 |
| Stocks Analysis by Zacks Investment Research covering: Ardelyx Inc. Read Zacks Investment Research's latest article on Investing.com | |
| Ardelyx to Present at the 10th Annual SV... | 02/17/21 |
| FREMONT, Calif., Feb. 17, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-cla... | |
| Ardelyx to Present at the Piper Sandler ... | 11/23/20 |
| FREMONT, Calif., Nov. 23, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-cla... | |
| Ardelyx to Webcast Virtual Analyst Day | 11/06/20 |
| FREMONT, Calif., Nov. 6, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines... | |
| Ardelyx Reports Third Quarter 2020 Finan... | 11/05/20 |
| FREMONT, Calif., Nov. 5, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative f... | |
| Ardelyx Is it time to Buy before this we... | 11/04/20 |
| Ardelyx announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| Irritable Bowel Syndrome Treatment Marke... | 11/01/20 |
| Irritable bowel syndrome is a gastrointestinal disorder of gut that may be identified by colon muscle contraction. It majorly affects the large intest... | |
| Ardelyx Inc (NASDAQ:ARDX) to Post Q3 202... | 10/24/20 |
| Ardelyx Inc (NASDAQ:ARDX) ??? Stock analysts at SVB Leerink increased their Q3 2020 earnings per share estimates for Ardelyx in a research report issu... | |
| Ardelyx Inc (NASDAQ:ARDX) Forecasted to ... | 10/22/20 |
| Ardelyx Inc (NASDAQ:ARDX) ??? SVB Leerink upped their Q3 2020 EPS estimates for Ardelyx in a research note issued on Tuesday, October 20th. SVB Leerin... | |
| Ardelyx and Kyowa Kirin Highlight New Da... | 10/22/20 |
| FREMONT, Calif. and TOKYO, Oct. 22, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company developing targeted, first-in-class... | |
| Ardelyx Launches 'Can We Do Better?' Cam... | 10/22/20 |
| FREMONT, Calif., Oct. 22, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company developing targeted, first-in-class medicines... | |
| Zacks: Analysts Anticipate Ardelyx Inc (... | 10/20/20 |
| Brokerages expect Ardelyx Inc (NASDAQ:ARDX) to post $1.37 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two... | |
| Why This FDA Win for Ardelyx Is Definite... | 09/15/20 |
| No summary available. | |
| Ardelyx Announces FDA Acceptance for Fil... | 09/15/20 |
| FREMONT, Calif., Sept. 15, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicin... | |
| Ardelyx to Participate in Three Upcoming... | 09/08/20 |
| FREMONT, Calif., Sept. 8, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicine... | |
| Ardelyx Reports Second Quarter 2020 Fina... | 08/06/20 |
| FREMONT, Calif., Aug. 6, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative f... | |
| Ardelyx Selected as a Finalist in the Fi... | 08/03/20 |
| FREMONT, Calif., Aug. 3, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative f... | |
| Ardelyx Appoints Veteran Biopharma Execu... | 06/08/20 |
| FREMONT, Calif., June 8, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative f... | |
| Ardelyx Strengthens Management Team with... | 05/18/20 |
| FREMONT, Calif., May 18, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative f... | |
| Will Ardelyx Continue to Surge Higher? | 05/12/20 |
| As of late, it has definitely been a great time to be an investor Ardelyx | |
| Ardelyx (ARDX) Upgraded to Strong Buy: H... | 05/11/20 |
| Ardelyx (ARDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). | |
| Strong Buy rating | 03/23/21 |
| Wedbush initiates coverage with Outperform rating and announces Price Target of $14.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Biotechnology | Robert Gadimian | 26.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
